Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
TuHURA Biosciences, Inc. is a clinical-stage immuno-oncology company developing innovative cancer therapies. Its core focus is on innate immune agonists and tumor microenvironment modulators, including bi-specific antibody-peptide conjugates and antibody-drug conjugates targeting myeloid-derived suppressor cells. The company aims to overcome resistance to immunotherapies, enhance immune responses, and expand treatment options for various cancers through proprietary technologies and strategic collaborations.
This description was generated via AI from an annual report. Updated about 1 year ago.